Barclays PLC Coherus Bio Sciences, Inc. Call Options Transaction History

Barclays PLC

6 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q1 2024 May 15, 2024	BUY	$2.02 - $3.14 $100,798 - $156,686	49,900 New	49,900 $119,000
Q4 2019 Feb 10, 2020	SELL	$16.33 - $21.37 $84,915 - $111,124	-5,200 Reduced 98.11%	100 $2,000
Q1 2019 May 15, 2019	BUY	$8.38 - $15.5 $2,514 - $4,650	300 Added 6.0%	5,300 $72,000
Q4 2018 Feb 14, 2019	BUY	$8.65 - $16.28 $42,385 - $79,772	4,900 Added 4900.0%	5,000 $45,000
Q1 2018 May 15, 2018	SELL	$9.1 - $13.7 $2,730 - $4,110	-300 Reduced 75.0%	100 $1,000
Q4 2017 Feb 14, 2018	BUY	$8.35 - $14.4 $3,340 - $5,760	400	400 $4,000

143

82.7M

79.1K

100K

Ticker CHRS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 77,724,600
Market Cap $81.6M
Description
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company markets UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte stimulating colony factor in the United States. Its pipeline products include biosimilars of Humira, Avastin, and Lucentis. T...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.